Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMT-253 |
| Synonyms | |
| Therapy Description |
AMT-253 is an antibody-drug conjugate (ADC) comprising an antibody that targets MUC18 linked to the topoisomerase I inhibitor exatecan and a linker T moiety, which may induce cytotoxicity against MUC18-expressing tumor cells and inhibit tumor growth (PMID: 37668527). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMT-253 | AMT 253|AMT253 | AMT-253 is an antibody-drug conjugate (ADC) comprising an antibody that targets MUC18 linked to the topoisomerase I inhibitor exatecan and a linker T moiety, which may induce cytotoxicity against MUC18-expressing tumor cells and inhibit tumor growth (PMID: 37668527). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05906862 | Phase I | AMT-253 | AMT-253 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 0 |